Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application for litazone drugs

A new use and drug technology, applied in the field of new use of ketones, can solve the problems of poor response to UDCA, no significant improvement in the mortality rate and liver transplantation rate of PSC patients, and limited curative effect of cholestatic liver disease

Inactive Publication Date: 2017-12-08
HEFEI UNIV OF TECH
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

UDCA is effective for most PBC, but there are still a considerable number of PBC patients who do not respond well to UDCA
In addition, UDCA has very limited efficacy on other types of cholestatic liver diseases, and has no significant improvement in the mortality rate and liver transplantation rate of PSC patients
Although the drugs for the treatment of PBC also include TUDCA (TUDCA is the combined form of taurine and UDCA, mainly for patients with poor response to UDCA) or S-adenosyl-L-methionine (S-adenosyl-L-methionine), glucocorticoids Combined with other immunosuppressants, fenofibrate (fenofibrate) and UDCA, but the efficacy of the above-mentioned drugs on PSC patients is very limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application for litazone drugs
  • New application for litazone drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0014] The embodiments of the present invention are described in detail below. This embodiment is implemented on the premise of the technical solution of the present invention, and detailed implementation methods and specific operating procedures are provided, but the protection scope of the present invention is not limited to the following implementation example.

[0015] Wild-type C57BL / 6J mice (8 weeks old) were randomly divided into four groups: control group, ANIT group, rosiglitazone+ANIT group, UDCA+ANIT group. The mice in the rosiglitazone+ANIT group were given rosiglitazone (dissolved in olive oil, the dose was 30 mg / kg body weight) for 3 consecutive days; the UDCA+ANIT group were given UDCA (dissolved in olive oil, the dose was 50 mg / kg body weight) for 3 consecutive days, and the control group and ANIT group were fed with the same amount of olive oil for 3 consecutive days. On the fourth day, the ANIT group, the rosiglitazone+ANIT group, and the UDCA+ANIT group wer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a new application for litazone drugs. The new application is characterized in that the litazone drugs used as the drugs for preventing and / or treating cholestatic liver disease have the effect better than that of the drug UDCA used in clinic at present.

Description

technical field [0001] The invention relates to a new application of proketones. Background technique [0002] Cholestatic liver disease refers to a pathological state in which bile acids are abnormally formed, secreted, and excreted due to various reasons inside and outside the liver, and cannot flow into the duodenum normally but enter the blood. Clinical manifestations include itching, fatigue, dark urine, and jaundice. Usually asymptomatic in the early stage, but the levels of ALP or AKP (alkaline phosphatase, alkaline phosphatase) and γ-GT (γ-glutamyl transferase, γ-glutamyl transferase) in the serum increase, and high bilirubin appears in the advanced stage of the disease Hepatic fibrosis, liver cirrhosis, severe cases can lead to liver failure and even death. Cholestasis persisting for more than 6 months is called chronic cholestasis. [0003] Clinically, according to the site of occurrence, it is divided into hepatocellular cholestasis, bile duct cholestasis and m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4439A61P1/16
CPCA61K31/4439
Inventor 韩际宏段亚君于淼张爽杨潇潇陈元利梁宇韩浩
Owner HEFEI UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com